Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecleralimab (CSJ117) in mild atopic asthma
NCT03138811Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Fab Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial comparing CSJ117 with Placebo (2 arms). Primary endpoints: Number of adverse events and serious adverse events at 12 weeks, Late asthmatic response as measured by the AUC for time adjusted percent decrease in FEV1 at 12 weeks and 1 more. Started Dec 2017; status: completed.
02
Drugs
ecleralimab
Beyond the preview
Go deeper on NCT03138811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138811.